FI4294257T3 - Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi - Google Patents
Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksiInfo
- Publication number
- FI4294257T3 FI4294257T3 FIEP22708698.0T FI22708698T FI4294257T3 FI 4294257 T3 FI4294257 T3 FI 4294257T3 FI 22708698 T FI22708698 T FI 22708698T FI 4294257 T3 FI4294257 T3 FI 4294257T3
- Authority
- FI
- Finland
- Prior art keywords
- chain variable
- seq
- amino acid
- acid sequence
- set forth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4869—Determining body composition
- A61B5/4872—Body fat
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/482—Diagnostic techniques involving multiple energy imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
- A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Data Mining & Analysis (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biotechnology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Artificial Intelligence (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dentistry (AREA)
- Software Systems (AREA)
- Bioethics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Evolutionary Computation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152100P | 2021-02-22 | 2021-02-22 | |
| PCT/US2022/017222 WO2022178382A1 (en) | 2021-02-22 | 2022-02-22 | Method for diagnosing and treating partial lipodystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4294257T3 true FI4294257T3 (fi) | 2025-12-19 |
Family
ID=80683255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22708698.0T FI4294257T3 (fi) | 2021-02-22 | 2022-02-22 | Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240153638A1 (https=) |
| EP (1) | EP4294257B1 (https=) |
| JP (1) | JP2024512255A (https=) |
| DK (1) | DK4294257T3 (https=) |
| ES (1) | ES3055018T3 (https=) |
| FI (1) | FI4294257T3 (https=) |
| HR (1) | HRP20251599T1 (https=) |
| LT (1) | LT4294257T (https=) |
| PL (1) | PL4294257T3 (https=) |
| PT (1) | PT4294257T (https=) |
| RS (1) | RS67523B1 (https=) |
| SI (1) | SI4294257T1 (https=) |
| SM (1) | SMT202500444T1 (https=) |
| WO (1) | WO2022178382A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| PT3773713T (pt) * | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
-
2022
- 2022-02-22 EP EP22708698.0A patent/EP4294257B1/en active Active
- 2022-02-22 JP JP2023550240A patent/JP2024512255A/ja active Pending
- 2022-02-22 LT LTEPPCT/US2022/017222T patent/LT4294257T/lt unknown
- 2022-02-22 HR HRP20251599TT patent/HRP20251599T1/hr unknown
- 2022-02-22 PT PT227086980T patent/PT4294257T/pt unknown
- 2022-02-22 SI SI202230205T patent/SI4294257T1/sl unknown
- 2022-02-22 US US18/547,150 patent/US20240153638A1/en active Pending
- 2022-02-22 DK DK22708698.0T patent/DK4294257T3/da active
- 2022-02-22 SM SM20250444T patent/SMT202500444T1/it unknown
- 2022-02-22 WO PCT/US2022/017222 patent/WO2022178382A1/en not_active Ceased
- 2022-02-22 FI FIEP22708698.0T patent/FI4294257T3/fi active
- 2022-02-22 RS RS20251266A patent/RS67523B1/sr unknown
- 2022-02-22 ES ES22708698T patent/ES3055018T3/es active Active
- 2022-02-22 PL PL22708698.0T patent/PL4294257T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022178382A1 (en) | 2022-08-25 |
| SI4294257T1 (sl) | 2026-01-30 |
| JP2024512255A (ja) | 2024-03-19 |
| US20240153638A1 (en) | 2024-05-09 |
| HRP20251599T1 (hr) | 2026-01-30 |
| DK4294257T3 (da) | 2025-12-08 |
| SMT202500444T1 (it) | 2026-01-12 |
| RS67523B1 (sr) | 2026-01-30 |
| PL4294257T3 (pl) | 2026-02-09 |
| EP4294257A1 (en) | 2023-12-27 |
| LT4294257T (lt) | 2025-12-29 |
| PT4294257T (pt) | 2025-11-28 |
| EP4294257B1 (en) | 2025-11-05 |
| ES3055018T3 (en) | 2026-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4294257T3 (fi) | Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi | |
| JP2024512255A5 (https=) | ||
| JP6377348B2 (ja) | ＴＧＦ−βアンタゴニストを使用する心筋梗塞の処置 | |
| FI3773713T3 (fi) | Leptiinireseptorin agonistivasta-aine käytettäväksi luumassan lisäämiseen aineenvaihdunnan toimintahäiriöstä tai hypoleptinemiasta kärsivällä yksilöllä | |
| JP2020500852A5 (https=) | ||
| WO2003059372A2 (en) | Combined use of a glp-1 compound and a modulator of diabetic late complications | |
| TW201305196A (zh) | 包含長效胰島素接合物與長效促胰島素肽接合物之用以治療糖尿病之組成物 | |
| EP3185881B1 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
| JP2024524159A (ja) | 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤 | |
| CA2573439C (en) | Compositions and methods for treating myocardial fibrosis comprising vasoactive intestinal peptide | |
| US20050129691A1 (en) | Method for treating anxiety and mood disorders in older subjects | |
| JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
| WO2011022334A1 (en) | Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes | |
| CA2757076C (en) | Compositions and methods for treatment of aortic fibrosis comprising vasoactive intestinal peptide (vip) or functional vip fragments | |
| CA2624648A1 (en) | Methods of decreasing vascular calcification using il-1 inhibitors | |
| WO2007143004A2 (en) | Methods, compositions, and kits for treating shiga toxin associated conditions | |
| US20070161551A1 (en) | Methods and compositions for the treatment of lipodystrophy | |
| JPH06510754A (ja) | 食欲不振および関連症状の治療用のアミリンおよび可能性としてインスリンを含有する組成物 | |
| TW202317110A (zh) | 用於治療肝臟疾病的聯合治療 | |
| CZ297743B6 (cs) | Pouzití acetyl-L-karnitinu ve spojení s biotinem k lécbe pacientu s diabetem mellitus typu 2 rezistentním na inzulín | |
| Pietroletti et al. | Enteroglucagon and peptide YY response after construction of a pelvic reservoir in humans | |
| EP1722778A1 (en) | Methods and compositions for the treatment of lipodystrophy | |
| CN1354676A (zh) | 用于心血管疾病疗法的氨基四氢化萘衍生物 | |
| WO2026072993A1 (en) | Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody | |
| JP2025147719A (ja) | 腎機能障害改善剤 |